Search Results - "Eisenberg, Peter"

A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors by Smith, David C, Eisenberg, Peter D, Manikhas, Georgy, Chugh, Rashmi, Gubens, Matthew A, Stagg, Robert J, Kapoun, Ann M, Xu, Lu, Dupont, Jakob, Sikic, Branimir

“…This phase I trial evaluated the safety, pharmacokinetics, and pharmacodynamics of demcizumab (OMP-21M18), a humanized IgG2 mAb targeting the Notch ligand DLL4…”
Get full text

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane by BURSTEIN, Harold J, ELIAS, Anthony D, BAUM, Charles M, MILLER, Kathy D, RUGO, Hope S, COBLEIGH, Melody A, WOLFF, Antonio C, EISENBERG, Peter D, LEHMAN, Mary, ADAMS, Bonne J, BELLO, Carlo L, DEPRIMO, Samuel E

“…Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor…”
Get full text

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer by KARP, Daniel D, PAZ-ARES, Luis G, JOHNSON, Faye M, GREEN, Stephanie, GUALBERTO, Antonio, NOVELLO, Silvia, HALUSKA, Paul, GARLAND, Linda, CARDENAL, Felipe, JOHNETTA BLAKELY, L, EISENBERG, Peter D, LANGER, Corey J, BLUMENSCHEIN, George

“…We conducted a phase II study of combination of the anti-insulin-like growth factor 1 receptor antibody CP-751,871 with paclitaxel and carboplatin (PCI) in…”
Get full text

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer by Haura, Eric B, Ricart, Alejandro D, Larson, Timothy G, Stella, Philip J, Bazhenova, Lyudmila, Miller, Vincent A, Cohen, Roger B, Eisenberg, Peter D, Selaru, Paulina, Wilner, Keith D, Gadgeel, Shirish M

“…To evaluate the efficacy of mitogen-activated protein kinase/extracellular signal-related kinase kinase inhibitor PD-0325901 in advanced non-small cell lung…”
Get full text

Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings by Cohen, Lorenzo, de Moor, Carl A, Eisenberg, Peter, Ming, Eileen E, Hu, Henry

“…The present study sought to determine the prevalence of acute and delayed chemotherapy-induced nausea and vomiting (CINV) across ten community oncology…”
Get full text

Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy by WARR, David G, HESKETH, Paul J, BOHIDAR, Norman, KLINGER, George, HUSTAD, Carolyn M, HORGAN, Kevin J, SKOBIERANDA, Franck, GRALLA, Richard J, MUSS, Hyman B, HERRSTEDT, Jam, EISENBERG, Peter D, RAFTOPOULOS, Harry, GRUNBERG, Steven M, GABRIEL, Munir, RODGERS, Anthony

“…This is the first study in which the NK(1)-receptor antagonist, aprepitant (APR), was evaluated for the prevention of chemotherapy-induced nausea and vomiting…”
Get full text

Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial by MEYERS, Christina A, SMITH, Jennifer A, SIEMERS, Ross, CARRIE, Christian, GASPAR, Laurie E, CURRAN, Walter, PHAN, See-Chun, MILLER, Richard A, RENSCHLER, Markus F, BEZJAK, Andrea, MEHTA, Minesh P, LIEBMANN, James, ILLIDGE, Tim, KUNKLER, Lan, CAUDRELIER, Jean-Michel, EISENBERG, Peter D, MEERWALDT, Jacobus

“…To report the neurocognitive findings in a phase III randomized trial evaluating survival and neurologic and neurocognitive function in patients with brain…”
Get full text

Improvement in Oncology Practice Performance Through Voluntary Participation in the Quality Oncology Practice Initiative by JACOBSON, Joseph O, NEUSS, Michael N, MCNIFF, Kristen K, KADLUBEK, Pamela, THACKER, Leroy R, SONG, Frank, EISENBERG, Peter D, SIMONE, Joseph V

“…The Quality Oncology Practice Initiative (QOPI) became available to all American Society of Clinical Oncology member physicians in 2006 as a voluntary medical…”
Get full text

A Process for Measuring the Quality of Cancer Care: The Quality Oncology Practice Initiative by NEUSS, Michael N, DESCH, Christopher E, SIMONE, Joseph V, MCNIFF, Kristen K, EISENBERG, Peter D, GESME, Dean H, JACOBSON, Joseph O, JAHANZEB, Mohammad, PADBERG, Jennifer J, RAINEY, John M, GUO, Jeff J

“…The Quality Oncology Practice Initiative (QOPI) is a practice-based system of quality self-assessment sponsored by the participants and the American Society of…”
Get full text

Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion by Rosen, Lee S., Gordon, David H., Dugan, William, Major, Pierre, Eisenberg, Peter D., Provencher, Louise, Kaminski, Mary, Simeone, Joe, Seaman, John, Chen, Bee‐Lian, Coleman, Robert E.

“…BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1…”
Get full text

Development and future of the American Society of Clinical Oncology's Quality Oncology Practice Initiative by Blayney, Douglas W, McNiff, Kristen, Eisenberg, Peter D, Gilmore, Terry, Jacobsen, Paul B, Jacobson, Joseph O, Kadlubek, Pamela J, Neuss, Michael N, Simone, Joseph

Get full text

Measuring Supportive Care in Medical Oncology Practice: Lessons Learned From the Quality Oncology Practice Initiative by McNiff, Kristen K, Neuss, Michael N, Jacobson, Joseph O, Eisenberg, Peter D, Kadlubek, Pamela, Simone, Joseph V

“…We provide a brief review of the use of quality measures to assess supportive care in the medical oncology office. Specifically, we discuss the development and…”
Get full text

Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer by FIELDS, Anthony L. A, KELLER, Alan, SCHWARTZBERG, Lee, BERNARD, Stephen, KARDINAL, Carl, COHEN, Alan, SCHULZ, Joe, EISENBERG, Peter, FORSTER, John, WISSEL, Paul

“…Edrecolomab (ED) is a murine monoclonal antibody targeting the EpCam antigen. This phase III randomized multicenter trial investigated the benefit of adding ED…”
Get full text

Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer by Belani, Chandra P, Nemunaitis, John J, Chachoua, Abraham, Eisenberg, Peter D, Raez, Luiz E, Cuevas, J Daniel, Mather, Cecile B, Benner, Rebecca J, Meech, Sandra J

“…This phase 2 study assessed PF-3512676 plus erlotinib in patients with epidermal growth factor receptor-positive advanced non-small cell lung cancer after…”
Get full text

Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer by DOUILLARD, Jean-Yves, HOFF, Paulo M, BENNER, Steven E, SKILLINGS, Jamey R, EISENBERG, Peter, DAVIDSON, Neville, HARPER, Peter, VINCENT, Mark D, LEMBERSKY, Barry C, THOMPSON, Seth, MANIERO, Antonella

“…This phase III study was designed to demonstrate equivalence in survival of oral uracil/tegafur (UFT) and oral leucovorin (LV) to conventional intravenous (IV)…”
Get full text

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy by Herrstedt, Jørn, Muss, Hyman B., Warr, David G., Hesketh, Paul J., Eisenberg, Peter D., Raftopoulos, Harry, Grunberg, Steven M., Gabriel, Munir, Rodgers, Anthony, Hustad, Carolyn M., Horgan, Kevin J., Skobieranda, Franck

“…BACKGROUND An aprepitant (APR) regimen was evaluated for prevention of nausea and emesis due to moderately emetogenic chemotherapy (MEC) over multiple cycles…”
Get full text

Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin by Karp, Daniel D, Pollak, Michael N, Cohen, Roger B, Eisenberg, Peter D, Haluska, Paul, Yin, Donghua, Lipton, Allan, Demers, Laurence, Leitzel, Kim, Hixon, Mary L, Terstappen, Leon W, Garland, Linda, Paz-Ares, Luis G, Cardenal, Felipe, Langer, Corey J, Gualberto, Antonio

“…This phase 1 study was conducted to determine the recommended phase 2 dose of the selective insulin-like growth factor type 1 receptor (IGF-IR) inhibitor…”
Get more information

Evolution and elements of the quality oncology practice initiative measure set by Neuss, Michael N, Jacobson, Joseph O, McNiff, Kristen K, Kadlubek, Pamela, Eisenberg, Peter D, Simone, Joseph V

“…Over the past 5 years, the American Society of Clinical Oncology (ASCO) has supported the development of a Web-based quality-reporting tool in response to a…”
Get more information

Caring for patients at the end of life by Eisenberg, Peter D

Get full text

Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial by Lønning, P E, Bajetta, E, Murray, R, Tubiana-Hulin, M, Eisenberg, P D, Mickiewicz, E, Celio, L, Pitt, P, Mita, M, Aaronson, N K, Fowst, C, Arkhipov, A, di Salle, E, Polli, A, Massimini, G

“…To evaluate the antitumor activity and toxicity of a new steroidal aromatase inactivator, exemestane, in postmenopausal women with metastatic breast cancer who…”
Get full text